Literature DB >> 3934382

Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.

D T Chu, P B Fernandes, A K Claiborne, E Pihuleac, C W Nordeen, R E Maleczka, A G Pernet.   

Abstract

A series of novel arylfluoroquinolones has been prepared. These derivatives are characterized by having a fluorine atom at the 6-position, substituted amino groups at the 7-position, and substituted phenyl groups at the 1-position. Structure-activity relationship (SAR) studies indicate that the in vitro antibacterial potency is greatest when the 1-substituent is either p-fluorophenyl or p-hydroxyphenyl and the 7-substituent is either 1-piperazinyl, 4-methyl-1-piperazinyl, or 3-amino-1-pyrrolidinyl. The electronic and spatial properties of the 1-substituent, as well as the steric bulk, play important roles in the antimicrobial potency in this class of antibacterials. As a result of this study, compounds 45 and 41 were found to possess excellent in vitro potency and in vivo efficacy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934382     DOI: 10.1021/jm00149a003

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Structure-activity relationships of the fluoroquinolones.

Authors:  D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.

Authors:  Chengxin Zhi; Zheng-Yu Long; Andrzej Manikowski; Jeanne Comstock; Wei-Chu Xu; Neal C Brown; Paul M Tarantino; Karsten A Holm; Edward J Dix; George E Wright; Marjorie H Barnes; Michelle M Butler; Kimberly A Foster; William A LaMarr; Benoit Bachand; Richard Bethell; Caroline Cadilhac; Sylvie Charron; Serge Lamothe; Irina Motorina; Richard Storer
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

3.  Synthesis of chromone, quinolone, and benzoxazinone sulfonamide nucleosides as conformationally constrained inhibitors of adenylating enzymes required for siderophore biosynthesis.

Authors:  Curtis A Engelhart; Courtney C Aldrich
Journal:  J Org Chem       Date:  2013-07-12       Impact factor: 4.354

4.  Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; M Esteve; M Moros; R Coll; M A Xicota; C de Andres; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

5.  Computer automated structure evaluation of quinolone antibacterial agents.

Authors:  G Klopman; O T Macina; M E Levinson; H S Rosenkranz
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

6.  Antibacterial activity and pharmacokinetics of four new 7-azetidinyl fluoroquinolones.

Authors:  R Coll; D Gargallo-Viola; E Tudela; M A Xicota; S Llovera; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 8.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

9.  E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.

Authors:  J Guinea; D Gargallo-Viola; M Robert; E Tudela; M A Xicota; J Garcia; M Esteve; R Coll; M Pares; R Roser
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Identification of the Beer Component Hordenine as Food-Derived Dopamine D2 Receptor Agonist by Virtual Screening a 3D Compound Database.

Authors:  Thomas Sommer; Harald Hübner; Ahmed El Kerdawy; Peter Gmeiner; Monika Pischetsrieder; Timothy Clark
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.